Platelet activation and aggregation machinery

The platelet activation and aggregation machinery represents the integrated system of cell surface receptors, intracellular signaling pathways, and effector proteins that govern the platelet response to vascular injury [1]. This machinery includes critical therapeutic targets such as the P2Y12 ADP receptor, the protease-activated receptor 1 (PAR-1), and the glycoprotein IIb/IIIa integrin complex [2]. Under physiological conditions, this system ensures hemostasis by forming a platelet plug; however, its overactivation leads to arterial thrombosis, a primary cause of myocardial infarction and ischemic stroke [3]. Antiplatelet drugs target specific nodes within this machinery, such as COX-1 (inhibited by aspirin) or P2Y12 (inhibited by clopidogrel), to reduce the risk of thrombotic events [4]. The therapeutic management of this machinery is complex, as inhibiting these pathways inherently increases the risk of bleeding complications [5]. Consequently, monitoring platelet function through various biomarkers is often employed to optimize treatment efficacy and safety [6].

Other names

Platelet activation pathwayPlatelet aggregation cascadeHemostatic machineryThrombotic signaling network

Inhibition of various components including cyclooxygenase-1 (COX-1) to prevent thromboxane A2 synthesis, antagonism of P2Y12 purinergic receptors to block ADP-induced activation, blockade of glycoprotein IIb/IIIa receptors to prevent fibrinogen cross-linking, and antagonism of protease-activated receptor-1 (PAR-1) to inhibit thrombin-mediated signaling.